Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter ended March 31, 2008. The Company reported revenues of $10.8M in the first quarter of 2008, compared to $9.2M in the first quarter of 2007. The net loss for the quarter ended March 31, 2008 was $13.1M, or $0.34 per share, compared to a net loss for the quarter ended March 31, 2007 of $8.8M, or $0.30 per share.

Research and development (R&D) expenses were $21.9M in the first quarter of 2008, compared to R&D expenses of $16.2M in the first quarter of 2007. The increase is primarily attributable to costs associated with the advancement of clinical programs, the costs related to manufacturing lead drug candidates and the increase in personnel related costs, which included an increase in the non-cash share-based compensation charge.

General and administrative (G&A) expenses for the first quarter of 2008 were $2.9M compared to G&A expenses of $2.4M for the same quarter in 2007. The higher G&A expenses were primarily due to an increase in professional fees and personnel related costs.

As of March 31, 2008, the Company had cash, cash equivalents and investments of $81.2 million.

"Our financial flexibility and stability will allow us to pursue all of the significant milestones we have set forth for our pipeline candidates," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "2008 will be a very active year in the clinic for BioCryst, and we are fortunate to have the financial basis to advance our drug candidates in order to deliver the greatest value to both patients and our shareholders."

Recent Corporate Highlights

Forodesine HCl cutaneous T-cell lymp
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 While administrative claims and ... research for a relatively long period of time, ... the use of these ‘big data’ for comparisons ... combining today’s powerful computer technology with the plethora ... data’ holds significant promise for identifying optimal interventions ...
(Date:7/30/2014)... , July 30, 2014   Wyle ... the Fully Integrated Lifecycle Mission Support Services (FILMSS) ... Administration (NASA). Under the terms of the contract, ... Center at Moffett Field, Calif. In particular, Wyle ... bioscience flight development projects on the International Space ...
(Date:7/30/2014)... July 30, 2014 BCC Research ( ... Markets for Enzymes in Industrial Applications , the global ... nearly $7.1 billion by 2018, registering a five-year compound ... estimated to be recorded in the detergent enzyme segment ... , Enzyme technology has influenced almost every sector of ...
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. ... received the Day 180 List of Outstanding Issues (LOI) ... for Human Use (CHMP) for the NB32 Marketing Authorization ... SR) is an investigational drug candidate being evaluated for ... earlier Day 120 time point were adequately addressed by ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... 2011 Arecor, the leading company ... and vaccines, is pleased to announce the appointment ... Howell will be responsible for the operations of ... Arecor,s upward growth curve ensuring the company continues ...
... Nov. 10, 2011 Avaxia Biologics, Inc. , ... act locally within the gastrointestinal tract, announced today that ... of a Series A angel-led financing. Cherrystone Angels of ... Boston Harbor Angels and other undisclosed individuals. Mr. Robert ...
... Discovery Laboratories, Inc. (Nasdaq: DSCO ), ... respiratory critical care, today reports financial results for the third ... of the SURFAXIN® and AFECTAIR™ programs.  The Company will host ... call details are below. Selected third quarter highlights ...
Cached Biology Technology:Arecor Appoints Dr. Sarah Howell as Chief Operating Officer 2Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 3Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 4Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 5Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 6Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 7Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 8Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 9
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... , July 30, 2014 NexID ... and liveness detection solutions for the biometric authentication ... industry consortium revolutionizing online authentication with standards for ... Cornett , "The decision to join FIDO Alliance ... authentication pervasive in use. We believe the FIDO ...
(Date:7/30/2014)... out how to create colors, nature had already perfected ... many different hues, for example. Now scientists are tapping ... way to make colored plastics. Their paper on using ... rather than dyes, to produce color appears in ... Asger Mortensen, Anders Kristensen and colleagues point out that ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2NexID Biometrics Joins the FIDO Alliance 2
... Va. A five-year-old Virginia Tech outreach program, ... doing research and providing results that scientists can ... Partnership Award from the National Center for Research ... of Health. The Fralin Life Science Institute,s Partnership ...
... If you would like to receive Science Picks via e-mail, ... to receive it, please e-mail kcapelli@usgs.gov . October ... Sumatra Earthquakes, DOI Prepared to Address Climate Change, Water is ... of Seismic Proportions, Forget the Garlic Necklace! Learn More about ...
... attention to National Child Health Day (today), the Preventive Cardiovascular ... consumer survey and launched a campaign to educate families about ... The national survey revealed that more than three in ... heart disease do not begin until adulthood. ...
Cached Biology News:NIH funds new phase of high school-university research partnership 2NIH funds new phase of high school-university research partnership 3USGS Science Picks 2USGS Science Picks 3USGS Science Picks 4USGS Science Picks 5USGS Science Picks 6USGS Science Picks 7USGS Science Picks 8USGS Science Picks 9Americans concerned about heart health, but not proactive enough to prevent it 2
...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... 4000 incorporates the critical design features demanded ... biomarker research. The Series 4000 delivers improved ... biomarker discoveries to biomarker assays all on ... designed to fit into the research plans ...
Gelatin 100 mm Culture Dishes...
Biology Products: